Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMET-C1 phase 3 trial of acoltremon eye drops for dry eye disease
CTR20260953Phase 3Active
- Sponsor
- Alcon Inc.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye syndrome (DED) comparing Acoltremon eye drops with Vehicle control (2 arms). Primary endpoint: Unanesthetized Schirmer test. Started Apr 2026; status: active.
02
Drugs
acoltremon
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20260953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260953.